#United States #Salt Lake City #Sera Prognostics #Maternal Health #PreTRM Test

Sera Prognostics Announces Proposed Public Offering

Sera Prognostics, Inc., known as The Pregnancy Company®, has recently unveiled its plans for a new underwritten public offering. The company aims to enhance maternal and neonatal health through groundbreaking biomarker information specifically designed for healthcare providers and expectant mothers. This initiative, aimed at expanding its commercial capabilities, reflects Sera's commitment to improving pregnancy-related health outcomes.

Details of the Offering

The proposed offering includes Class A common stock and pre-funded warrants for certain investors, providing flexibility and access to equity for potential investors. Sera will grant its underwriters a 30-day option to purchase additional shares, which could increase the offering size by up to 15%, depending on market conditions.

Underwriters for this public offering include Jefferies, TD Cowen, and William Blair, with RBC Capital Markets joining as a bookrunner. Notably, the final size and terms of this offering remain subject to market conditions, highlighting the ever-changing nature of financial markets.

Utilization of Proceeds

Sera Prognostics intends to leverage the proceeds from this public offering for several crucial initiatives:

1. Expanded U.S. Operations: Strengthening its commercial infrastructure to address the increasing demand for its services.
2. European Expansion: Preparing its services for broader access within the European Union.
3. Enhancing the PreTRM Test: Conducting further studies to increase adoption rates for their PreTRM test, which predicts the risk of premature delivery, including a potential filing for FDA approval for the test.
4. Corporate Purposes: General corporate needs, indicating a broad and strategic approach to growth.

Regulatory Filing

To facilitate this offering, Sera has filed a shelf registration statement with the Securities and Exchange Commission (SEC). This filing process, which included registering the securities with the SEC, is essential for ensuring regulatory compliance and provides a pathway for future offerings. A preliminary prospectus will be available on the SEC’s website for interested investors.

Company Background and Vision

Founded with the objective to revolutionize maternal care, Sera Prognostics focuses on delivering precise healthcare solutions through test diagnostics. Their specialized PreTRM test is designed to report on the individual risks associated with spontaneous preterm birth, enabling healthcare providers to implement early interventions.

With headquarters in Salt Lake City, Utah, Sera Prognostics is setting a robust example in healthcare innovation. The company emphasizes not just the health outcomes for mothers and babies but also the financial implications of advanced diagnostic tools in reducing healthcare delivery costs.

As Sera Prognostics moves forward with this public offering, it marks a significant step in its journey to enhance maternal healthcare, promising an increased focus on prevention and early intervention in prenatal care. This potential influx of funds could facilitate a series of advancements in their existing technologies and broaden the scope of their analytics to assist more families in their pregnancy journeys.

Conclusion

Overall, the move to propose a public offering underscores Sera Prognostics' commitment to its mission of improving maternal and neonatal health. By expanding its operational capabilities both domestically and internationally, the company is strategic in ensuring it is positioned to meet future challenges in healthcare while continuing to lead in pregnancy diagnostics and early intervention solutions.